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Abstract. Herein, we discussed a new problem concerning diagnosis, treatment, and monitoring of patients with 
intestinal candidosis. The lack of official attitude about the significance of Candida overgrowth on intestinal mucosa as 
well as the absence of guidelines regarding its treatment and required diet, significantly complicate this problem in 
medical practice. Possible overgrowth of species Saccharomyces cerevisiae-bulardi from probiotics in intestines is a 
newly recognized problem in diagnostic procedures. 




The role of Candida spp. in the etiology of gastrointesti-
nal disturbances, infection, and diseases hasn't been 
clarified yet. Gastrointestinal candidosis is still a subject 
of controversy in scientific circles without a unique 
opinion about pathogenic potential of this yeast, 
interpretation of mycological analysis result, and, most 
importantly, without referral guidelines for its treatment. 
Lack of official recommendations regarding this prob-
lem, alongside a huge number of unreliable theories and 
misbeliefs in referent literature, electronic media and 
newspapers, have confused both scientists and laymen 
since the 1980s [1-3]. 
Valid Postulates 
We can point out following facts:  
 It is well known that Candida spp. represent the 
part of gut microbiota (normal gastrointestinal 
flora) in healthy people, but in certain cases, 
these commensal fungi can convert from non-
pathogenic to pathogenic ones [4]. 
 The most important Candida infections of the 
gastrointestinal tract are esophageal and gastroin-
testinal candidosis in severely immunocompro-
mised. Esophageal candidosis is usually seen in 
AIDS patients or those receiving long-term 
chemotherapy. In addition, patients with leuke-
mia and other hematologic malignancies are at 
increased risk for the development of multiple 
ulcers on the intestinal mucosa due to fungal in-
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fection. Thus, gastrointestinal perforation and 
complications such as peritonitis or hematog-
enous spread of fungi to the liver, spleen, and 
lungs are common in these patients [5]. 
 A big portion of healthy, immunocompetent, peo-
ple having Candida spp. in their digestive system as 
part of microbiota, therefore have positive labora-
tory findings (positive Candida-isolates from the 
stool samples). For this reason, the discrimination 
between Candida-colonization and Candida-infec-
tion is difficult [6]. 
 Unlike obligate pathogens, whose detection im-
plies disease, differential diagnosis between Can-
dida-infection and Candida-colonization is more 
complex. In order to make a distinction, it is nec-
essary to perform endoscopic biopsy and subse-
quent histopathological examination. This is the 
reason why there is still no unique approach re-
garding the treatment of patients with gastrointes-
tinal candidosis and there are a lot of questionable 
viewpoints regarding the pathogenic effect of 
Candida on the intestinal mucosa.  
 Regardless of many controversial postulates about 
pathogenic potential of Candida, current opinion 
in medical theory and praxis is that Candida spp. 
has a role in the occurrence of diarrhea after 
antibiotic consumption. Consequently, nystatin 
prophylaxis is recommended during the antibacte-
rial treatment [7]. 
 The theory that immune dysregulation in intesti-
nal mucosa, specifically IgE-mediated reaction to 
Candida antigens, actually leads to local and sys-
temic damage of tissues is under investigation [8]. 
 There is still no official recommendation for anti-
fungal “intestinal decontamination”. However the 
use of nystatin showed satisfactory anti-Candida 
effect with reduction and even complete withdrawal 
of symptoms in patients with diarrhea [7, 9]. 
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Current Consideration and Observation  
The presence of Candida yeast as a member of microbi-
ota on intestinal mucosa is mainly benign. However, the 
results of the newest research concerning Candida spp. 
impact on the digestive tract, demonstrated that, if pre-
sent, these yeasts may contribute to the destruction of 
already damaged mucosa. Studies that included patients 
with gastrointestinal diseases and the ones done on ani-
mal models, without a doubt revealed that presence of 
Candida may lead to an even bigger defect and massive 
inflammation [10-13]. 
Investigation of Crohn’s disease and the presence of 
Candida on intestinal mucosa established the relationship 
between this inflammatory bowel disease and intestinal 
Candida colonization [10]. Furthermore, it was demon-
strated that antifungal treatment to reduce Candida-colo-
nization lessens the severity of ulcerative colitis [11]. 
Moreover, analysis of the animal model suggested that 
Candida colonization may create a vicious cycle where 
yeasts slow down the healing of inflammatory lesions 
while inflammation promotes fungal colonization [12]. 
There is also an assumption that if Candida can cause 
infection and inflammation of the skin, severe damage of 
nail, inflammation of vulvovaginal mucosa, pseudomem-
branous and erythematous oral candidosis, as well as 
perianal eczema, then it can as well have a pathogenic 
effect at the level of the intestinal mucosa. 
Problems 
In addition to these still unresolved issues, in practice, 
there are also problems of diagnosis and patients treat-
ment. Candida spp. can, under the influence of various 
factors, multiply rapidly and overgrow the rest of gut 
microbiota, leading to dysbiosis. Based on this simpli-
fied, long-standing, concept and on our experience in 
routine work with patients who have Candida infec-
tion/colonization of digestive tract, we can point out that 
physicians usually prescribe local antimycotic, with or 
without a diet, but recommendation of probiotics is 
practically mandatory. The role of microorganisms con-
tained inside a probiotic supplement is to successfully 
colonize intestinal mucosa, stay resistant to the influ-
ence of other microorganisms, and persist in intestines. 
The use of these supplement products increases the 
possibility of gut colonization with non-pathogenic mi-
crobes and preservation of normal balance among usual 
members of physiologic flora [14].In the best-case sce-
nario, this treatment will improve condition in a certain 
number of patients with dysbiosis. However, some of 
them, despite antifungal treatment, will have recurrent 
episodes, and will require repeated mycological 
examination of the stool. 
Our Experience and New Problem 
Our previous study [2] as well as the records of approxi-
mately 80,000 patients examined in our mycological la-
boratory, showed that in over 60% of cases there are pos-
itive findings of Candida  in the stool samples. Never-
theless, the percentage of patients with Candida over-
growth (>106 CFU/g of faeces) is significantly lower (8-
10%). Interestingly, in a ten-year period, 2% of examined 
patients had positive findings of yeast overgrowth with 
causative species being Saccharomyces (S.) cerevisiae. 
This is a ubiquitous ascomycetous yeast that colonizes 
the respiratory, urinary and gastrointestinal tract of 
humans and is traditionally considered non-pathogenic. 
Recently, however, it has started to be considered as a 
potential pathogen and cause of superficial and invasive 
fungal infection. Accordingly, S. cerevisiae overgrowth 
on intestinal mucosa could be as problematic as Candida 
-overgrowth. On the other hand, S. cerevisiae-bulardi 
strain is a component of many probiotics and can quickly 
proliferate during prolonged treatment. In order to cor-
rectly interpret the findings of S. cerevisiae, we decided 
to have an interview with 100 patients. All of them, ex-
cept one, stated that, according to physician recommen-
dation, they have used probiotics that contain S. cere-
visiae-bulardi strain for more than 20 days.  
Besides previously stated problems that there is no 
general opinion about Candida-overgrowth on the 
intestinal mucosa and official guidelines regarding treat-
ment and diet for this condition are lacking, additional 
problems are being recognized:  
 Mycological analyses of the stool can suggest 
yeast overgrowth, yet it can be overgrowth of 
yeast from probiotics.  
 In Serbia there are only a few microbiological la-
boratories equipped for mycological analysis and 
even fewer for differentiation of yeast strains. 
 During the mycological analysis of the stool, over-
growth of Saccharomyces yeasts from probiotics 
can be easily mistaken for high counts of Candida 
spp. Therefore, only in case of macroscopic and 
microscopic examination,, misinterpretation of re-
sult as Candida overgrowth may occur. 
 Errors in result interpretation, as well as the fact 
that most physicians are neither familiar with the 
latest trends in mycology, nor with the risk that 
yeasts from probiotics can lead to Saccharomy-
ces overgrowth on the intestinal mucosa, may 
subsequently mislead the doctor to start „treating 
the treatment“[15,16]. 
To conclude, it would be best to establish laboratory 
capacity for differentiation between Candida and Sac-
charomyces yeast; to implement purposeful education 
for both medical personnel and laymen which would 
enable regular patient follow-ups; and before mycologi-
cal analysis of intestinal microbiota to obtained anam-
nestic data of each patient regarding disturbance of gas-
trointestinal tract and consummation of probiotics, as 
well as the duration of this kind of treatment. Finally, 
the most correct interpretation of mycological examina-
tion can be provided only by a multidisciplinary team 
and patient participation.  
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